Bowden Christopher 4

What Happened
Christopher Bowden, a director of Bicara Therapeutics, received an award of derivative securities on 2026-06-09: options covering 19,475 shares (reported as acquisition code "A"), with an exercise/transaction price of $0.00 and total reported value $0. This is a grant of options/awarded derivative securities — not an open-market purchase or sale — and the shares underlying the award are subject to vesting.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (timely filing).
• Instrument: Derivative securities (option award) covering 19,475 shares; reported price $0.00.
• Vesting: Footnote — underlying shares vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders, subject to continued service.
• Shares owned after transaction: not specified in the provided filing.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding, or cashless exercise noted.

Context
This is a non-cash option grant that vests in the future; it does not represent an immediate purchase or sale of company stock. Such awards are common for directors and align compensation with future service and performance but do not by themselves indicate near-term buying or selling intent.